- Home
- BNR vs PYPD Comparison
BNR vs PYPD Comparison
Compare BNR & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- PYPD
- Stock Information
- Founded
- BNR 2014
- PYPD 2008
- Country
- BNR China
- PYPD Israel
- Employees
- BNR N/A
- PYPD N/A
- Industry
- BNR Medical Specialities
- PYPD Medical/Dental Instruments
- Sector
- BNR Health Care
- PYPD Health Care
- Exchange
- BNR Nasdaq
- PYPD Nasdaq
- Market Cap
- BNR 29.1M
- PYPD 26.7M
- IPO Year
- BNR 2020
- PYPD 2020
- Fundamental
- Price
- BNR $3.10
- PYPD $2.80
- Analyst Decision
- BNR
- PYPD Strong Buy
- Analyst Count
- BNR 0
- PYPD 2
- Target Price
- BNR N/A
- PYPD $10.50
- AVG Volume (30 Days)
- BNR 68.0K
- PYPD 37.2K
- Earning Date
- BNR 06-10-2025
- PYPD 05-14-2025
- Dividend Yield
- BNR N/A
- PYPD N/A
- EPS Growth
- BNR N/A
- PYPD N/A
- EPS
- BNR N/A
- PYPD N/A
- Revenue
- BNR $70,669,261.00
- PYPD N/A
- Revenue This Year
- BNR $136.32
- PYPD N/A
- Revenue Next Year
- BNR N/A
- PYPD N/A
- P/E Ratio
- BNR N/A
- PYPD N/A
- Revenue Growth
- BNR N/A
- PYPD N/A
- 52 Week Low
- BNR $2.18
- PYPD $2.30
- 52 Week High
- BNR $7.90
- PYPD $4.67
- Technical
- Relative Strength Index (RSI)
- BNR 51.73
- PYPD 52.30
- Support Level
- BNR $2.99
- PYPD $2.44
- Resistance Level
- BNR $3.45
- PYPD $3.00
- Average True Range (ATR)
- BNR 0.34
- PYPD 0.25
- MACD
- BNR 0.10
- PYPD -0.01
- Stochastic Oscillator
- BNR 70.59
- PYPD 42.86
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.